Moderna (MRNA) EBT (2017 - 2026)

Moderna (MRNA) has 10 years of EBT data on file, last reported at -$1.3 billion in Q1 2026.

• On a quarterly basis, EBT fell 38.38% year-over-year to -$1.3 billion in Q1 2026; TTM through Mar 2026 was -$3.1 billion, a 7.87% increase from a year earlier, with the FY2025 full-year figure at -$2.8 billion, up 23.26% from the prior year.
• EBT for Q1 2026 stood at -$1.3 billion, down from -$799.0 million in the prior quarter.
• Over the last five years, EBT for MRNA reached as high as $4.2 billion in Q1 2022 and fell as low as -$2.0 billion in Q3 2023.
• Historically, EBT has averaged -$122.1 million across 5 years, with a median of -$799.0 million in 2025.
• Across the five-year window, EBT jumped 235.63% in 2022 and sank 1791.43% in 2024, its largest moves.
• Year by year, EBT stood at $1.7 billion in 2022, then sank by 95.77% to $70.0 million in 2023, then sank by 1791.43% to -$1.2 billion in 2024, then soared by 32.52% to -$799.0 million in 2025, then plunged by 66.96% to -$1.3 billion in 2026.
• Per Business Quant data, the three most recent EBT figures were -$1.3 billion in Q1 2026, -$799.0 million in Q4 2025, and -$187.0 million in Q3 2025.